Ultrasound Transducer Disinfection in many Cases insufficient

New ‘Trophon EPR’ Device offers unique Solution

--------------------------------------------------------------------------------
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
the content of this announcement.
--------------------------------------------------------------------------------

innovations

Hamburg (euro adhoc) - Current methods of ultrasound transducer
disinfection are in many cases not sufficient for clinical practice.
This is the latest alarming result issued by the Center for Disease
Control and Prevention (CDC), the leading US public health agency, in
its recently published Guideline for Disinfection and Sterilization
in Healthcare Facilities. (1) The guideline is the CDC´s response to
the rapidly evolving epidemiology of hospital-acquired infections
such as Clostridium difficile (2) or MRSA (3).

In light of this global threat, and with regard to the millions of
ultrasound examinations conducted each day, Nanosonics´ newest
product innovation represents a long-needed milestone in the
development of medical devices: due to its unique technology, the
Trophon EPR completely satisfies all requirements of the new CDC
guideline.

Whereas current methods for high-level disinfection of contaminated
transvaginal and transrectal transducers (e.g. aldehydes, alcohol or
chlorine) show considerable drawbacks, the Trophon EPR has been
custom designed to disinfect intracavity and surface ultrasound
transducers, while combining speed, safety and convenience. It
delivers high-level disinfection plus (HLD+), including sporicidal
efficacy, in only six minutes operating time. The fully automated
device can be used directly at the point of care, is easy to operate
and is environmentally friendly, leaving water and oxygen as the only
by-products.

The Trophon EPR was officially presented at this year´s MEDICA, which
took place in Düsseldorf, Germany, from 19 to 22 November, 2008. "We
recognised the danger presented by the inadequate disinfection of
ultrasound transducers, and know that the Trophon EPR will be
indispensable for the urgently needed hygiene necessary in the
medical sector, to guarantee the safety of each and every patient",
explained David Radford, Director and CEO of Nanosonics Limited,
Australia, prior to the impending market launch.

The product technology has been validated by major OEM´s (e.g.
Philips) and dealer commitments have already been approved in several
European countries. The European launch of the Trophon EPR is
scheduled to start in the first half of 2009. For more information
about Nanosonics, the Trophon EPR and its platform technology
(NanoNebulant™) please visit the Company´s websites at
www.nanosonics.eu and www.trophon.com.au.

About Nanosonics

The company is of Australian origin, located in Alexandria, Sydney,
with European headquarters in Hamburg, Germany. Nanosonics has been
listed on the Australian Securities Exchange (NAN) and Frankfurt
Stock Exchange (OQM) since 2007.

The company owns intellectual property relating to unique
disinfection and sterilisation technologies, which can be suited to a
variety of markets including the healthcare industry, food
processing, room and space decontamination, and manufacturing.

Nanosonics is currently focused on developing infection control
solutions for the global healthcare market. Initial applications are
designed for the reprocessing of reusable medical instruments. The
Trophon EPR is specifically designed to disinfect intracavity and
surface ultrasound probes. Based on the NanoNebulant™ technology it
surpasses the limitations of current methods by killing the most
resilient micro-organisms, in a fast, safe and convenient way.

(1) Rutala WA, Weber DJ, Healthcare Infection Control Practices
Advisory Committee. Guideline for Disinfection and Sterilization in
Healthcare Facilities, 2008.
http://www.cdc.gov/ncidod/dhqp/sterile.html.

(2) Association for Professionals in Infection Control and
Epidemiology (APIC). Press release, Orlando, 11 November 2008:
Intestinal infection afflicts 13 of 1,000 hospital patients;
infection rates 6.5-20 times greater than previous estimates, new
study says.

(3) Orsi GB. MRSA: an old and new enemy. Healthcare Infection 2008;
13:73-75.

World Headquarters
Nanosonics Ltd.
Unit 24, 566 Gardeners Road
Alexandria NSW 2015
Australia
http://www.nanosonics.com.au

European Headquarters
Nanosonics Europe GmbH
Falkenried 88, House E
20251 Hamburg
Germany
http://www.nanosonics.eu

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: NANOSONICS LTD.
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Nikola Heimann

Telefon: +49(0)40-35543624

E-Mail: nikola.heimann@plus-pool.de

Branche: Biotechnology
ISIN: AU000000NAN9
WKN: A0MQVE
Börsen: Börse Berlin / Open Market
Börse Frankfurt / Open Market